After gaining more than 22 per cent in the past week, Ipca Laboratories shed some of the gains on Monday. Investors, including mutual funds, have been buying the stock in the hope that the pressure on earnings has bottomed out and the inspections of its plants, as well as growth in the India business, would lead to upgrades. The stock had hit a peak of nearly Rs 900 in 2014 before correcting by over 40 per cent to the current levels, following import alerts imposed by the US FDA on its three key plants at Silvassa, Indore and Ratlam. Nitin Agarwal and Sumit Singhania of IDFC ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?